First-Line Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab Continue to Demonstrate OS Benefit in Patients with Advanced Oesophageal Squamous Cell Carcinoma By Ogkologos - September 1, 2026 39 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the 5-year follow-up of the CheckMate 648 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Researchers Discover New Way to Prevent Hair Loss During Chemotherapy Treatment September 12, 2019 World Cancer Day 2023: where does the UK stand? February 3, 2023 Development of T-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy July 22, 2024 EMA Recommends Granting a Marketing Authorisation for Germanium (68Ge) chloride /... June 28, 2024 Load more HOT NEWS Aiming to Prevent New Cancer Cases, ESMO Calls for Increased Minimum... Rebuilding My Life After Cancer and Intensive Treatment: A Survivor’s Story Can I Have a Non-Violent Relationship with Cancer (Part 2) Stopping neuropathy: One of chemotherapy’s most challenging side effects
